[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  BioTech Visionary [@BioTechVisions](/creator/twitter/BioTechVisions) on x XX followers Created: 2025-07-23 19:38:49 UTC 🚀 Dispatch Bio Raises $216M to Launch Solid Tumor CAR‑T Innovation with Carl June at Helm 🌟 Big leap forward in cancer therapy! Dispatch Bio, a brainchild of CAR‑T innovator Carl June, M.D., has raised $XXX million to launch its first-in-class Flare™ platform aimed at universal solid tumor treatment. This platform introduces a novel antigen via viral vector to tag tumors and reprogram the microenvironment—enabling deep immune responses without harming healthy cells. With scientific roots from labs led by June, Andy Minn, Chris Garcia, and Kole Roybal, Dispatch is bridging advanced immunology and engineering to tackle ~90% of cancers currently resistant to CAR‑T. Backed by ARCH Venture and Parker Institute, the company is poised to redefine what's possible in cancer care. 💡 #CancerImmunotherapy #DispatchBio #CAR-T #CarlJune #SolidTumors #Biotech #Innovation #FlarePlatform  XX engagements  **Related Topics** [$216m](/topic/$216m) [Post Link](https://x.com/BioTechVisions/status/1948105539793412510)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
BioTech Visionary @BioTechVisions on x XX followers
Created: 2025-07-23 19:38:49 UTC
🚀 Dispatch Bio Raises $216M to Launch Solid Tumor CAR‑T Innovation with Carl June at Helm 🌟
Big leap forward in cancer therapy! Dispatch Bio, a brainchild of CAR‑T innovator Carl June, M.D., has raised $XXX million to launch its first-in-class Flare™ platform aimed at universal solid tumor treatment. This platform introduces a novel antigen via viral vector to tag tumors and reprogram the microenvironment—enabling deep immune responses without harming healthy cells.
With scientific roots from labs led by June, Andy Minn, Chris Garcia, and Kole Roybal, Dispatch is bridging advanced immunology and engineering to tackle ~90% of cancers currently resistant to CAR‑T. Backed by ARCH Venture and Parker Institute, the company is poised to redefine what's possible in cancer care. 💡
#CancerImmunotherapy #DispatchBio #CAR-T #CarlJune #SolidTumors #Biotech #Innovation #FlarePlatform
XX engagements
Related Topics $216m